ES2368879T3 - Pirimidinas antiinfecciosas y usos de las mismas. - Google Patents

Pirimidinas antiinfecciosas y usos de las mismas. Download PDF

Info

Publication number
ES2368879T3
ES2368879T3 ES08832330T ES08832330T ES2368879T3 ES 2368879 T3 ES2368879 T3 ES 2368879T3 ES 08832330 T ES08832330 T ES 08832330T ES 08832330 T ES08832330 T ES 08832330T ES 2368879 T3 ES2368879 T3 ES 2368879T3
Authority
ES
Spain
Prior art keywords
group
independently selected
alkyl
optionally substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08832330T
Other languages
English (en)
Spanish (es)
Inventor
Charles A. Flentge
Douglas K. Hutchinson
David A. Betebenner
David A. Degoey
Pamela L. Donner
Warren M. Kati
Allan C. Krueger
Dachun Liu
Yaya Liu
Kenton L. Longenecker
Clarence J. Maring
Christopher E. Motter
John K. Pratt
John T. Randolph
Todd W. Rockway
Kent D. Stewart
Rolf Wagner
David M. Barnes
Shuang Chen
Thaddeus S. Ii Franczyk
Yi Gao
Anthony R. Haight
John E. Hengeveld
Brian J. Kotecki
Xiaochun Lou
Geoff G. Z. Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2368879T3 publication Critical patent/ES2368879T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ES08832330T 2007-09-17 2008-09-17 Pirimidinas antiinfecciosas y usos de las mismas. Active ES2368879T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96792 1998-06-12
US97288107P 2007-09-17 2007-09-17
US972881P 2007-09-17
US9679208P 2008-09-13 2008-09-13

Publications (1)

Publication Number Publication Date
ES2368879T3 true ES2368879T3 (es) 2011-11-23

Family

ID=40308557

Family Applications (3)

Application Number Title Priority Date Filing Date
ES08832330T Active ES2368879T3 (es) 2007-09-17 2008-09-17 Pirimidinas antiinfecciosas y usos de las mismas.
ES11171399.6T Active ES2523864T3 (es) 2007-09-17 2008-09-17 Pirimidinas antiinfecciosas y usos de las mismas
ES12182277.9T Active ES2592961T3 (es) 2007-09-17 2008-09-17 Pirimidinas antiinfecciosas y usos de las mismas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES11171399.6T Active ES2523864T3 (es) 2007-09-17 2008-09-17 Pirimidinas antiinfecciosas y usos de las mismas
ES12182277.9T Active ES2592961T3 (es) 2007-09-17 2008-09-17 Pirimidinas antiinfecciosas y usos de las mismas

Country Status (21)

Country Link
US (3) US8188104B2 (enExample)
EP (3) EP2639226B1 (enExample)
JP (3) JP5734655B2 (enExample)
CN (4) CN104628654A (enExample)
AT (1) ATE519746T1 (enExample)
CA (2) CA2849420C (enExample)
CY (3) CY1115514T1 (enExample)
DK (3) DK2368882T3 (enExample)
ES (3) ES2368879T3 (enExample)
HR (2) HRP20110809T1 (enExample)
HU (1) HUS1500013I1 (enExample)
LT (1) LTC2203431I2 (enExample)
LU (1) LU92666I2 (enExample)
MX (1) MX2010002902A (enExample)
NL (1) NL300729I2 (enExample)
NO (1) NO2015011I1 (enExample)
PL (3) PL2639226T3 (enExample)
PT (3) PT2368882E (enExample)
RU (2) RU2539570C2 (enExample)
SI (2) SI2368882T1 (enExample)
WO (1) WO2009039134A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693626A (zh) 2007-09-17 2016-06-22 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN104628654A (zh) * 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
CN102746239B (zh) * 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
WO2010010017A1 (en) * 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2334662A1 (en) 2008-09-26 2011-06-22 F. Hoffmann-La Roche AG Pyrine or pyrazine derivatives for treating hcv
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
RU2552533C2 (ru) * 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения
EP2421831A1 (en) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
SG176976A1 (en) 2009-06-24 2012-02-28 Hoffmann La Roche Heterocyclic antiviral compound
BR112012005616A2 (pt) 2009-09-21 2016-06-21 Hoffmann La Roche compostos antivirais heterocíclicos
JP5699152B2 (ja) 2009-09-25 2015-04-08 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． リジン特異的デメチラーゼ−１阻害剤およびその使用
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
BR112012012085A2 (pt) * 2009-11-21 2016-05-17 Hoffmann La Roche compostos antivirais heterocíclicos
BR112012014299A2 (pt) * 2009-12-14 2016-07-05 Hoffmann La Roche composto de antivírus heterocíclicos
KR20120093428A (ko) * 2009-12-14 2012-08-22 메르크 파텐트 게엠베하 스핑고신 키나아제 저해제
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
JP5868948B2 (ja) 2010-04-19 2016-02-24 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． リジン特異的脱メチル化酵素１阻害薬およびその使用
EP3461556A1 (en) 2010-07-16 2019-04-03 AbbVie Ireland Unlimited Company Phosphine ligands for catalytic reactions
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
EP3056486B1 (en) * 2010-07-16 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing intermediates for antiviral compounds
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) * 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
SG11201401066PA (en) 2011-10-20 2014-10-30 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
EP2583680A3 (en) * 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2887941B1 (en) 2012-08-21 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing antiviral compounds
JP6266635B2 (ja) * 2012-10-18 2018-01-24 アッヴィ・インコーポレイテッド ピリミジンジオン誘導体化合物の製剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
CN108777958B (zh) * 2016-03-17 2021-03-12 Fmc有限公司 将s-对映体转换成其消旋形式的方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN108290844B (zh) * 2016-05-27 2021-04-30 深圳市塔吉瑞生物医药有限公司 一种取代的萘环化合物及药物组合物及其应用
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN117466847B (zh) * 2022-07-22 2026-01-27 中国医药工业研究总院有限公司 一种利非斯特中间体苯并呋喃-6-羧酸的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
ATE169915T1 (de) 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
NL9001075A (enExample) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
PL207160B1 (pl) 1999-12-06 2010-11-30 Hoffmann La Roche Pochodne 4-pirymidynylo-N-acylo-L-fenyloalaniny, związki pośrednie, środek farmaceutyczny i ich zastosowanie
IL167954A (en) 2000-02-04 2007-10-31 Sumitomo Chemical Co History of pyrimidine
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
BRPI0413234A (pt) * 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2008506702A (ja) * 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
WO2007058392A1 (ja) * 2005-11-21 2007-05-24 Japan Tobacco Inc. ヘテロ環化合物およびその医薬用途
CN102746239B (zh) * 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN105693626A (zh) 2007-09-17 2016-06-22 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN104628654A (zh) * 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
WO2010010017A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds

Also Published As

Publication number Publication date
NO2015011I1 (no) 2015-05-04
JP5734655B2 (ja) 2015-06-17
NL300729I1 (enExample) 2016-01-07
ES2592961T3 (es) 2016-12-02
JP2013056886A (ja) 2013-03-28
RU2010114827A (ru) 2011-10-27
PT2368882E (pt) 2014-11-27
EP2639226A1 (en) 2013-09-18
SI2368882T1 (sl) 2015-02-27
LTC2203431I2 (lt) 2017-01-25
EP2639226B1 (en) 2016-08-31
PL2639226T3 (pl) 2017-02-28
CY2015013I1 (el) 2016-04-13
US8501238B2 (en) 2013-08-06
CY1115893T1 (el) 2017-01-25
CY1115514T1 (el) 2016-04-13
DK2368882T3 (en) 2014-12-01
CA2699986A1 (en) 2009-03-26
ATE519746T1 (de) 2011-08-15
DK2639226T3 (en) 2016-12-19
US20140294766A1 (en) 2014-10-02
CN101842360B (zh) 2014-12-17
EP2368882B1 (en) 2014-08-13
CN101842360A (zh) 2010-09-22
RU2014147354A (ru) 2015-07-10
PT2639226T (pt) 2016-12-09
US8188104B2 (en) 2012-05-29
HRP20110809T1 (hr) 2011-12-31
MX2010002902A (es) 2010-06-02
HUS1500013I1 (hu) 2016-11-28
CN102746240A (zh) 2012-10-24
CN102746240B (zh) 2017-10-03
NL300729I2 (enExample) 2016-01-07
US9139536B2 (en) 2015-09-22
US20090186912A1 (en) 2009-07-23
EP2203431B1 (en) 2011-08-10
WO2009039134A1 (en) 2009-03-26
JP5931683B2 (ja) 2016-06-08
EP2203431A1 (en) 2010-07-07
CN104628655A (zh) 2015-05-20
CA2849420C (en) 2016-07-12
EP2368882A1 (en) 2011-09-28
SI2203431T1 (sl) 2011-12-30
RU2539570C2 (ru) 2015-01-20
HK1156033A1 (en) 2012-06-01
HK1148273A1 (en) 2011-09-02
LU92666I2 (fr) 2015-11-24
JP2010539187A (ja) 2010-12-16
US20120244119A1 (en) 2012-09-27
CN104628654A (zh) 2015-05-20
RU2014147354A3 (enExample) 2018-07-30
CA2699986C (en) 2014-06-17
CY2015013I2 (el) 2016-04-13
JP2015187106A (ja) 2015-10-29
DK2203431T3 (da) 2011-11-21
NO2015011I2 (no) 2015-04-22
PL2203431T3 (pl) 2012-01-31
ES2523864T3 (es) 2014-12-02
HRP20141102T1 (en) 2015-03-13
PT2203431E (pt) 2011-10-12
PL2368882T3 (pl) 2015-04-30
CA2849420A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
ES2368879T3 (es) Pirimidinas antiinfecciosas y usos de las mismas.
US8415351B2 (en) Anti-infective agents and uses thereof
RU2542099C2 (ru) N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
ES2413080T3 (es) Compuestos antivirales y usos de los mismos
ES2365650T3 (es) N-fenil-dioxo-hidroxipirimidinas útiles como inhibidores del virus de la hepatitis c (vhc).
HK1189590B (en) Anti-infective pyrimidines and uses thereof
HK1156033B (en) Anti-infective pyrimidines and uses thereof